



February 1, 2016

Chair Mitch Greenlick
House Committee on Health Care
Oregon House of Representatives
900 Court St. NE, H-493
Salem, Oregon 97301

Re: HB 4105 — Relating to biological products; declaring an emergency, to be considered by the House Committee on Health Care on February 3, 2016.

Dear Chair Greenlick,

All over the country, state legislatures are considering legislation, and many have already passed bills, to ensure that their residents have access to biosimilars and interchangeable biological products. We are at the beginning of a new age of biological therapies, and laws and regulations must reflect this new reality. HB 4105, to be considered by the Committee on Health Care on February 3, is an excellent example of legislation that does just that.

ICAN, the International Cancer Advocacy Network, is in strong support of HB 4105 because of its patient safety protections when dispensing interchangeable biological products. ICAN, a five-star rated 501(c)(3) charitable cancer patient advocacy organization, helps late-stage cancer patients in Oregon and throughout the country. We deal daily with biologic therapies for our U.S. patients, and for our patients in 53 countries. Biologic therapies, and thus interchangeable biological products, will become a growing area for metastatic cancer patients.

This is a particularly timely issue given the first approval of a biosimilar in the United States just last year, and the expected approval of many more in the future. HB 4105 ensures that when an FDA-approved, lower-cost, interchangeable biological product is substituted by a pharmacist for a brand-name biologic, records will be kept, and the pharmacist will communicate to the patient and prescribing physician the precise drug that was dispensed—thus ensuring patient safety.

Communication to the patient and physician is essential because, unlike generic drugs that are an exact copy, the interchangeable biological product can be slightly different due to manufacture, transportation, or handling. If a patient experiences any adverse reactions, a physician needs to know all possible causes, including and especially, that the patient received an interchangeable biological product. Failing to communicate to the patient and physician when a substitution is made is an unnecessary risk to patient safety.

While we acknowledge (and welcome) the economic impact on healthcare of interchangeable biological products, patient safety can easily be protected by requiring communication to the patient and physician. Because of their complexity, size, and sensitivity, all biologics—whether reference, biosimilar, or interchangeable biological products—have potential for unintended induction of potent, immunologic reactions. Each and every patient may respond differently to any biologic, depending on their individual genetics and immunologic status.

Dr. Greenlick, given your distinguished career in health care and health care research, and your leadership of the Committee, your support for HB 4105 in the hearing on February 3, and throughout the legislative process, is a powerful voice for the safety of ICAN's Oregon patients, and for all Oregon patients. It is also supporting well-crafted legislation that can serve as a model for other states.

Please do not hesitate to contact me at marcia@askican.org if you need additional information.

Thank you for your consideration, and for your support.

Respectfully submitted,

Marcia K. Horn

Marcia K. Horn, J.D.
President and CEO
International Cancer Advocacy Network (ICAN)
27 West Morten Avenue
Phoenix, AZ 85021-7246
602-618-0183 (phone)
602-926-8109 (fax)
www.askican.org
marcia@askican.org



February 1, 2016

Vice Chair Rob Nosse
House Committee on Health Care
Oregon House of Representatives
900 Court St. NE, H-472
Salem, Oregon 97301

Re: HB 4105 — Relating to biological products; declaring an emergency, to be considered by the House Committee on Health Care on February 3, 2016.

Dear Vice Chair Nosse,

Thank you so much for sponsoring HB 4105! We greatly appreciate your leadership on this issue and have written your fellow Health Care Committee members to urge that they support the bill in committee and throughout the legislative process.

ICAN, the International Cancer Advocacy Network, is in strong support of HB 4105 because of its patient safety protections when dispensing interchangeable biological products. ICAN, a five-star rated 501(c)(3) charitable cancer patient advocacy organization, helps late-stage cancer patients in Oregon and throughout the country. We deal daily with biologic therapies for our U.S. patients, and for our patients in 53 countries. Biologic therapies, and thus interchangeable biological products, will become a growing area for metastatic cancer patients.

This is a particularly timely issue given the first approval of a biosimilar in the United States just last year, and the expected approval of many more in the future. Your sponsorship of HB 4105, your support in the hearing on February 3 and throughout the legislative process, is a powerful voice for the safety of ICAN's Oregon patients, and for all Oregon patients. It is also sponsoring well-crafted legislation that can serve as a model for other states.

Please do not hesitate to contact me at marcia@askican.org if I can ever be of assistance.

Thank you for your consideration, and for your support.

Respectfully submitted,

Marcia K. Horn

Marcia K. Horn, J.D.
President and CEO
International Cancer Advocacy Network (ICAN)
27 West Morten Avenue
Phoenix, AZ 85021-7246
602-618-0183 (phone)
602-926-8109 (fax)
www.askican.org
marcia@askican.org



February 1, 2016

Vice Chair Cedric Hayden
House Committee on Health Care
Oregon House of Representatives
900 Court St. NE, H-379
Salem, Oregon 97301

Re: HB 4105 — Relating to biological products; declaring an emergency, to be considered by the House Committee on Health Care on February 3, 2016.

Dear Vice Chair Hayden,

All over the country, state legislatures are considering legislation, and many have already passed bills, to ensure that their residents have access to biosimilars and interchangeable biological products. We are at the beginning of a new age of biological therapies, and laws and regulations must reflect this new reality. HB 4105, to be considered by the Committee on Health Care on February 3, is an excellent example of legislation that does just that.

ICAN, the International Cancer Advocacy Network, is in strong support of HB 4105 because of its patient safety protections when dispensing interchangeable biological products. ICAN, a five-star rated 501(c)(3) charitable cancer patient advocacy organization, helps late-stage cancer patients in Oregon and throughout the country. We deal daily with biologic therapies for our U.S. patients, and for our patients in 53 countries. Biologic therapies, and thus interchangeable biological products, will become a growing area for metastatic cancer patients.

This is a particularly timely issue given the first approval of a biosimilar in the United States just last year, and the expected approval of many more in the future. HB 4105 ensures that when an FDA-approved, lower-cost, interchangeable biological product is substituted by a pharmacist for a brand-name biologic, records will be kept, and the pharmacist will communicate to the patient and prescribing physician the precise drug that was dispensed—thus ensuring patient safety.

Communication to the patient and physician is essential because, unlike generic drugs that are an exact copy, the interchangeable biological product can be slightly different due to manufacture, transportation, or handling. If a patient experiences any adverse reactions, a physician needs to know all possible causes, including and especially, that the patient received an interchangeable biological product. Failing to communicate to the patient and physician when a substitution is made is an unnecessary risk to patient safety.

While we acknowledge (and welcome) the economic impact on healthcare of interchangeable biological products, patient safety can easily be protected by requiring communication to the patient and physician. Because of their complexity, size, and sensitivity, all biologics—whether reference, biosimilar, or interchangeable biological products—have potential for unintended induction of potent, immunologic reactions. Each and every patient may respond differently to any biologic, depending on their individual genetics and immunologic status.

Your support for HB 4105 in the hearing on February 3, and throughout the legislative process, is a powerful voice for the safety of ICAN's Oregon patients, and for all Oregon patients. It is also supporting well-crafted legislation that can serve as a model for other states.

Please do not hesitate to contact me at marcia@askican.org if you need additional information.

Thank you for your consideration, and for your support.

Respectfully submitted,

Marcia K. Horn

Marcia K. Horn, J.D.
President and CEO
International Cancer Advocacy Network (ICAN)
27 West Morten Avenue
Phoenix, AZ 85021-7246
602-618-0183 (phone)
602-926-8109 (fax)
www.askican.org
marcia@askican.org



February 1, 2016

Rep. Knute Buehler
House Committee on Health Care
Oregon House of Representatives
900 Court St. NE, H-389
Salem, Oregon 97301

Re: HB 4105 — Relating to biological products; declaring an emergency, to be considered by the House Committee on Health Care on February 3, 2016.

Dear Rep. (and Dr.) Buehler,

All over the country, state legislatures are considering legislation, and many have already passed bills, to ensure that their residents have access to biosimilars and interchangeable biological products. We are at the beginning of a new age of biological therapies, and laws and regulations must reflect this new reality. HB 4105, to be considered by the Committee on Health Care on February 3, is an excellent example of legislation that does just that.

ICAN, the International Cancer Advocacy Network, is in strong support of HB 4105 because of its patient safety protections when dispensing interchangeable biological products. ICAN, a five-star rated 501(c)(3) charitable cancer patient advocacy organization, helps late-stage cancer patients in Oregon and throughout the country. We deal daily with biologic therapies for our U.S. patients, and for our patients in 53 countries. Biologic therapies, and thus interchangeable biological products, will become a growing area for metastatic cancer patients.

This is a particularly timely issue given the first approval of a biosimilar in the United States just last year, and the expected approval of many more in the future. HB 4105 ensures that when an FDA-approved, lower-cost, interchangeable biological product is substituted by a pharmacist for a brand-name biologic, records will be kept, and the pharmacist will communicate to the patient and prescribing physician the precise drug that was dispensed—thus ensuring patient safety.

Communication to the patient and physician is essential because, unlike generic drugs that are an exact copy, the interchangeable biological product can be slightly different due to manufacture, transportation, or handling. If a patient experiences any adverse reactions, a physician needs to know all possible causes, including and especially, that the patient received an interchangeable biological product. Failing to communicate to the patient and physician when a substitution is made is an unnecessary risk to patient safety.

While we acknowledge (and welcome) the economic impact on healthcare of interchangeable biological products, patient safety can easily be protected by requiring communication to the patient and physician. Because of their complexity, size, and sensitivity, all biologics—whether reference, biosimilar, or interchangeable biological products—have potential for unintended induction of potent, immunologic reactions. Each and every patient may respond differently to any biologic, depending on their individual genetics and immunologic status.

Dr. Buehler, given your distinguished career in medicine, your support for HB 4105 in the hearing on February 3, and throughout the legislative process, is a powerful voice for the safety of ICAN's Oregon patients, and for all Oregon patients. It is also supporting well-crafted legislation that can serve as a model for other states.

Please do not hesitate to contact me at marcia@askican.org if you need additional information.

Thank you for your consideration, and for your support.

Respectfully submitted,

Marcia K. Horn

Marcia K. Horn, J.D.
President and CEO
International Cancer Advocacy Network (ICAN)
27 West Morten Avenue
Phoenix, AZ 85021-7246
602-618-0183 (phone)
602-926-8109 (fax)
www.askican.org
marcia@askican.org



February 1, 2016

Rep. Brian Clem
House Committee on Health Care
Oregon House of Representatives
900 Court St. NE, H-284
Salem, Oregon 97301

Re: HB 4105 — Relating to biological products; declaring an emergency, to be considered by the House Committee on Health Care on February 3, 2016.

Dear Rep. Clem,

All over the country, state legislatures are considering legislation, and many have already passed bills, to ensure that their residents have access to biosimilars and interchangeable biological products. We are at the beginning of a new age of biological therapies, and laws and regulations must reflect this new reality. HB 4105, to be considered by the Committee on Health Care on February 3, is an excellent example of legislation that does just that.

ICAN, the International Cancer Advocacy Network, is in strong support of HB 4105 because of its patient safety protections when dispensing interchangeable biological products. ICAN, a five-star rated 501(c)(3) charitable cancer patient advocacy organization, helps late-stage cancer patients in Oregon and throughout the country. We deal daily with biologic therapies for our U.S. patients, and for our patients in 53 countries. Biologic therapies, and thus interchangeable biological products, will become a growing area for metastatic cancer patients.

This is a particularly timely issue given the first approval of a biosimilar in the United States just last year, and the expected approval of many more in the future. HB 4105 ensures that when an FDA-approved, lower-cost, interchangeable biological product is substituted by a pharmacist for a brand-name biologic, records will be kept, and the pharmacist will communicate to the patient and prescribing physician the precise drug that was dispensed—thus ensuring patient safety.

Communication to the patient and physician is essential because, unlike generic drugs that are an exact copy, the interchangeable biological product can be slightly different due to manufacture, transportation, or handling. If a patient experiences any adverse reactions, a physician needs to know all possible causes, including and especially, that the patient received an interchangeable biological product. Failing to communicate to the patient and physician when a substitution is made is an unnecessary risk to patient safety.

While we acknowledge (and welcome) the economic impact on healthcare of interchangeable biological products, patient safety can easily be protected by requiring communication to the patient and physician. Because of their complexity, size, and sensitivity, all biologics—whether reference, biosimilar, or interchangeable biological products—have potential for unintended induction of potent, immunologic reactions. Each and every patient may respond differently to any biologic, depending on their individual genetics and immunologic status.

Your support for HB 4105 in the hearing on February 3, and throughout the legislative process, is a powerful voice for the safety of ICAN's Oregon patients, and for all Oregon patients. It is also supporting well-crafted legislation that can serve as a model for other states.

Please do not hesitate to contact me at marcia@askican.org if you need additional information.

Thank you for your consideration, and for your support.

Respectfully submitted,

Marcia K. Horn

Marcia K. Horn, J.D.
President and CEO
International Cancer Advocacy Network (ICAN)
27 West Morten Avenue
Phoenix, AZ 85021-7246
602-618-0183 (phone)
602-926-8109 (fax)
www.askican.org
marcia@askican.org



February 1, 2016

Rep. Bill Kennemer
House Committee on Health Care
Oregon House of Representatives
900 Court St. NE, H-380
Salem, Oregon 97301

Re: HB 4105 — Relating to biological products; declaring an emergency, to be considered by the House Committee on Health Care on February 3, 2016.

Dear Rep. Kennemer,

All over the country, state legislatures are considering legislation, and many have already passed bills, to ensure that their residents have access to biosimilars and interchangeable biological products. We are at the beginning of a new age of biological therapies, and laws and regulations must reflect this new reality. HB 4105, to be considered by the Committee on Health Care on February 3, is an excellent example of legislation that does just that.

ICAN, the International Cancer Advocacy Network, is in strong support of HB 4105 because of its patient safety protections when dispensing interchangeable biological products. ICAN, a five-star rated 501(c)(3) charitable cancer patient advocacy organization, helps late-stage cancer patients in Oregon and throughout the country. We deal daily with biologic therapies for our U.S. patients, and for our patients in 53 countries. Biologic therapies, and thus interchangeable biological products, will become a growing area for metastatic cancer patients.

This is a particularly timely issue given the first approval of a biosimilar in the United States just last year, and the expected approval of many more in the future. HB 4105 ensures that when an FDA-approved, lower-cost, interchangeable biological product is substituted by a pharmacist for a brand-name biologic, records will be kept, and the pharmacist will communicate to the patient and prescribing physician the precise drug that was dispensed—thus ensuring patient safety.

Communication to the patient and physician is essential because, unlike generic drugs that are an exact copy, the interchangeable biological product can be slightly different due to manufacture, transportation, or handling. If a patient experiences any adverse reactions, a physician needs to know all possible causes, including and especially, that the patient received an interchangeable biological product. Failing to communicate to the patient and physician when a substitution is made is an unnecessary risk to patient safety.

While we acknowledge (and welcome) the economic impact on healthcare of interchangeable biological products, patient safety can easily be protected by requiring communication to the patient and physician. Because of their complexity, size, and sensitivity, all biologics—whether reference, biosimilar, or interchangeable biological products—have potential for unintended induction of potent, immunologic reactions. Each and every patient may respond differently to any biologic, depending on their individual genetics and immunologic status.

Your support for HB 4105 in the hearing on February 3, and throughout the legislative process, is a powerful voice for the safety of ICAN's Oregon patients, and for all Oregon patients. It is also supporting well-crafted legislation that can serve as a model for other states.

Please do not hesitate to contact me at marcia@askican.org if you need additional information.

Thank you for your consideration, and for your support.

Respectfully submitted,

Marcia K. Horn

Marcia K. Horn, J.D.
President and CEO
International Cancer Advocacy Network (ICAN)
27 West Morten Avenue
Phoenix, AZ 85021-7246
602-618-0183 (phone)
602-926-8109 (fax)
www.askican.org
marcia@askican.org



February 1, 2016

Rep. Alisa Keny-Guyer
House Committee on Health Care
Oregon House of Representatives
900 Court St. NE, H-484
Salem, Oregon 97301

Re: HB 4105 — Relating to biological products; declaring an emergency, to be considered by the House Committee on Health Care on February 3, 2016.

Dear Rep. Keny-Guyer,

All over the country, state legislatures are considering legislation, and many have already passed bills, to ensure that their residents have access to biosimilars and interchangeable biological products. We are at the beginning of a new age of biological therapies, and laws and regulations must reflect this new reality. HB 4105, to be considered by the Committee on Health Care on February 3, is an excellent example of legislation that does just that.

ICAN, the International Cancer Advocacy Network, is in strong support of HB 4105 because of its patient safety protections when dispensing interchangeable biological products. ICAN, a five-star rated 501(c)(3) charitable cancer patient advocacy organization, helps late-stage cancer patients in Oregon and throughout the country. We deal daily with biologic therapies for our U.S. patients, and for our patients in 53 countries. Biologic therapies, and thus interchangeable biological products, will become a growing area for metastatic cancer patients.

This is a particularly timely issue given the first approval of a biosimilar in the United States just last year, and the expected approval of many more in the future. HB 4105 ensures that when an FDA-approved, lower-cost, interchangeable biological product is substituted by a pharmacist for a brand-name biologic, records will be kept, and the pharmacist will communicate to the patient and prescribing physician the precise drug that was dispensed—thus ensuring patient safety.

Communication to the patient and physician is essential because, unlike generic drugs that are an exact copy, the interchangeable biological product can be slightly different due to manufacture, transportation, or handling. If a patient experiences any adverse reactions, a physician needs to know all possible causes, including and especially, that the patient received an interchangeable biological product. Failing to communicate to the patient and physician when a substitution is made is an unnecessary risk to patient safety.

While we acknowledge (and welcome) the economic impact on healthcare of interchangeable biological products, patient safety can easily be protected by requiring communication to the patient and physician. Because of their complexity, size, and sensitivity, all biologics—whether reference, biosimilar, or interchangeable biological products—have potential for unintended induction of potent, immunologic reactions. Each and every patient may respond differently to any biologic, depending on their individual genetics and immunologic status.

Your support for HB 4105 in the hearing on February 3, and throughout the legislative process, is a powerful voice for the safety of ICAN's Oregon patients, and for all Oregon patients. It is also supporting well-crafted legislation that can serve as a model for other states.

Please do not hesitate to contact me at marcia@askican.org if you need additional information.

Thank you for your consideration, and for your support.

Respectfully submitted,

Marcia K. Horn

Marcia K. Horn, J.D.
President and CEO
International Cancer Advocacy Network (ICAN)
27 West Morten Avenue
Phoenix, AZ 85021-7246
602-618-0183 (phone)
602-926-8109 (fax)
www.askican.org
marcia@askican.org



February 1, 2016

Rep. John Lively
House Committee on Health Care
Oregon House of Representatives
900 Court St. NE, H-488
Salem, Oregon 97301

Re: HB 4105 — Relating to biological products; declaring an emergency, to be considered by the House Committee on Health Care on February 3, 2016.

Dear Rep. Lively,

All over the country, state legislatures are considering legislation, and many have already passed bills, to ensure that their residents have access to biosimilars and interchangeable biological products. We are at the beginning of a new age of biological therapies, and laws and regulations must reflect this new reality. HB 4105, to be considered by the Committee on Health Care on February 3, is an excellent example of legislation that does just that.

ICAN, the International Cancer Advocacy Network, is in strong support of HB 4105 because of its patient safety protections when dispensing interchangeable biological products. ICAN, a five-star rated 501(c)(3) charitable cancer patient advocacy organization, helps late-stage cancer patients in Oregon and throughout the country. We deal daily with biologic therapies for our U.S. patients, and for our patients in 53 countries. Biologic therapies, and thus interchangeable biological products, will become a growing area for metastatic cancer patients.

This is a particularly timely issue given the first approval of a biosimilar in the United States just last year, and the expected approval of many more in the future. HB 4105 ensures that when an FDA-approved, lower-cost, interchangeable biological product is substituted by a pharmacist for a brand-name biologic, records will be kept, and the pharmacist will communicate to the patient and prescribing physician the precise drug that was dispensed—thus ensuring patient safety.

Communication to the patient and physician is essential because, unlike generic drugs that are an exact copy, the interchangeable biological product can be slightly different due to manufacture, transportation, or handling. If a patient experiences any adverse reactions, a physician needs to know all possible causes, including and especially, that the patient received an interchangeable biological product. Failing to communicate to the patient and physician when a substitution is made is an unnecessary risk to patient safety.

While we acknowledge (and welcome) the economic impact on healthcare of interchangeable biological products, patient safety can easily be protected by requiring communication to the patient and physician. Because of their complexity, size, and sensitivity, all biologics—whether reference, biosimilar, or interchangeable biological products—have potential for unintended induction of potent, immunologic reactions. Each and every patient may respond differently to any biologic, depending on their individual genetics and immunologic status.

Your support for HB 4105 in the hearing on February 3, and throughout the legislative process, is a powerful voice for the safety of ICAN's Oregon patients, and for all Oregon patients. It is also supporting well-crafted legislation that can serve as a model for other states.

Please do not hesitate to contact me at marcia@askican.org if you need additional information.

Thank you for your consideration, and for your support.

Respectfully submitted,

Marcia K. Horn

Marcia K. Horn, J.D.
President and CEO
International Cancer Advocacy Network (ICAN)
27 West Morten Avenue
Phoenix, AZ 85021-7246
602-618-0183 (phone)
602-926-8109 (fax)
www.askican.org
marcia@askican.org



February 1, 2016

Rep. Jim Weidner
House Committee on Health Care
Oregon House of Representatives
900 Court St. NE, H-387
Salem, Oregon 97301

Re: HB 4105 — Relating to biological products; declaring an emergency, to be considered by the House Committee on Health Care on February 3, 2016.

Dear Rep. Weidner,

All over the country, state legislatures are considering legislation, and many have already passed bills, to ensure that their residents have access to biosimilars and interchangeable biological products. We are at the beginning of a new age of biological therapies, and laws and regulations must reflect this new reality. HB 4105, to be considered by the Committee on Health Care on February 3, is an excellent example of legislation that does just that.

ICAN, the International Cancer Advocacy Network, is in strong support of HB 4105 because of its patient safety protections when dispensing interchangeable biological products. ICAN, a five-star rated 501(c)(3) charitable cancer patient advocacy organization, helps late-stage cancer patients in Oregon and throughout the country. We deal daily with biologic therapies for our U.S. patients, and for our patients in 53 countries. Biologic therapies, and thus interchangeable biological products, will become a growing area for metastatic cancer patients.

This is a particularly timely issue given the first approval of a biosimilar in the United States just last year, and the expected approval of many more in the future. HB 4105 ensures that when an FDA-approved, lower-cost, interchangeable biological product is substituted by a pharmacist for a brand-name biologic, records will be kept, and the pharmacist will communicate to the patient and prescribing physician the precise drug that was dispensed—thus ensuring patient safety.

Communication to the patient and physician is essential because, unlike generic drugs that are an exact copy, the interchangeable biological product can be slightly different due to manufacture, transportation, or handling. If a patient experiences any adverse reactions, a physician needs to know all possible causes, including and especially, that the patient received an interchangeable biological product. Failing to communicate to the patient and physician when a substitution is made is an unnecessary risk to patient safety.

While we acknowledge (and welcome) the economic impact on healthcare of interchangeable biological products, patient safety can easily be protected by requiring communication to the patient and physician. Because of their complexity, size, and sensitivity, all biologics—whether reference, biosimilar, or interchangeable biological products—have potential for unintended induction of potent, immunologic reactions. Each and every patient may respond differently to any biologic, depending on their individual genetics and immunologic status.

Your support for HB 4105 in the hearing on February 3, and throughout the legislative process, is a powerful voice for the safety of ICAN's Oregon patients, and for all Oregon patients. It is also supporting well-crafted legislation that can serve as a model for other states.

Please do not hesitate to contact me at marcia@askican.org if you need additional information.

Thank you for your consideration, and for your support.

Respectfully submitted,

Marcia K. Horn

Marcia K. Horn, J.D.
President and CEO
International Cancer Advocacy Network (ICAN)
27 West Morten Avenue
Phoenix, AZ 85021-7246
602-618-0183 (phone)
602-926-8109 (fax)
www.askican.org
marcia@askican.org

